Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Genesis Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,870,892

406 payments

Through program year 2025, Genesis Clinical Research is reported as receiving $3,870,892 in research payments, across 406 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,339,070 166
2024 Research $986,765 15
2023 Research $362,202 46
2022 Research $95,257 28
2021 Research $678,869 96
2020 Research $390,311 51
2019 Research $18,418 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $1,247,950 10 payments
  2. AbbVie, Inc. $785,245 134 payments
  3. United Therapeutics Corporation $600,269 16 payments
  4. Boehringer Ingelheim International GmbH $290,585 142 payments
  5. Novartis Pharmaceuticals Corporation $259,324 11 payments
  6. Merck Sharp & Dohme Corporation $225,765 9 payments
  7. Eli Lilly and Company $213,216 1 payment
  8. AstraZeneca UK Limited $82,072 9 payments
  9. Insmed, Inc. $64,376 5 payments
  10. GlaxoSmithKline, LLC. $46,810 15 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of Single Doses of VX 548 in Subjects with Severe or Moderate Renal Impairment and in Matched Healthy Subjects $898,504 2 payments
  2. An Evaluation of the Pharmacokinetics and Safety of a Single Dose of Ralinepag in Participants with Renal Impairment $330,370 8 payments
  3. A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Severe Renal Impairment and Healthy Subjects With Normal Renal Function $271,253 1 payment
  4. An Evaluation of the Pharmacokinetics and Safety of a Single Dose of Ralinepag in Participants with Hepatic Impairment $269,899 8 payments
  5. A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Participants with End Stage Renal Disease Receiving Hemodialysis. $225,765 9 payments
  6. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $216,446 61 payments
  7. Pharmacokinetics of Ly3537982 Following A Single Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function $213,216 1 payment
  8. M14-702 $201,117 21 payments
  9. A Phase 1, open-label study to investigate the pharmacokinetics and safety of remibrutinib (LOU064) in participants with severe renal impairment compared to matched healthy participants with normal renal function $169,459 1 payment
  10. A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $156,791 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record